INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 344 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2024. The put-call ratio across all filers is 0.66 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $13,218,570 | +69.0% | 193,000 | +70.8% | 5.39% | +74.2% |
| Q1 2024 | $7,819,600 | +53.8% | 113,000 | +59.2% | 3.10% | -10.3% |
| Q4 2023 | $5,085,020 | +248.6% | 71,000 | +153.6% | 3.45% | +353.6% |
| Q3 2023 | $1,458,520 | -72.4% | 28,000 | -72.0% | 0.76% | -71.7% |
| Q4 2022 | $5,292,000 | +13.7% | 100,000 | 0.0% | 2.69% | +57.6% |
| Q3 2022 | $4,653,000 | +8.7% | 100,000 | +33.3% | 1.71% | -0.4% |
| Q2 2022 | $4,281,000 | +210.9% | 75,000 | +233.3% | 1.71% | +271.6% |
| Q1 2022 | $1,377,000 | -54.1% | 22,500 | -74.5% | 0.46% | -44.6% |
| Q1 2021 | $2,997,000 | -38.5% | 88,326 | -42.4% | 0.83% | -54.3% |
| Q4 2020 | $4,876,000 | – | 153,348 | – | 1.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
| Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
| Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
| WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
| SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
| Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
| EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
| EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
| Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |